Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report

被引：1

作者：

Carbo-Bague, Anna ^{[1
,2
]}

Fort-Culillas, Roser ^{[1
]}

Pla-Juher, Helena ^{[1
]}

Rubio-Casadevall, Jordi ^{[1
,2
]}

机构：

[1] Catalan Inst Oncol, Med Oncol Dept, Girona, Spain

[2] Biomed Res Inst IDIBGI, Descript Epidemiol Genet & Canc Prevent Grp, Girona, Spain

来源：

CASE REPORTS IN ONCOLOGY | 2021年 / 14卷 / 03期

关键词：

Immune checkpoint inhibitors; Immune-related adverse event; Autoimmune haemolytic anaemia; Nivolumab; Ipilimumab;

D O I：

10.1159/000518530

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safeness of subsequent treatment with ipilimumab (anti-CTLA4). After the remission of AIHA with steroids, ipilimumab was started with the rationale of its different mechanism of action. Fortunately, AIHA did not recur. The mechanism by which checkpoint inhibitors cause AIHA is likely by augmenting or redirecting immune surveillance, especially by activating pre-existing red blood cell autoantibodies, but further studies must be done. To our knowledge, this is the first case published in the literature with the change of immunotherapy treatment to anti-CTLA4. (C) 2021 The Author(s). Published by S. Karger AG, Basel

引用

页码：1289 / 1294

页数：6

共 12 条

[11] Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report [J].

Tardy, Magalie P. ;

Gastaud, Lauris ;

Boscagli, Annick ;

Peyrade, Frederic ;

Gallamini, Andrea ;

Thyss, Antoine .

HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) :875-877

[12] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma [J].

Weber, J. ;

Mandala, M. ;

Del Vecchio, M. ;

Gogas, H. J. ;

Arance, A. M. ;

Cowey, C. L. ;

Dalle, S. ;

Schenker, M. ;

Chiarion-Sileni, V. ;

Marquez-Rodas, I. ;

Grob, J-J. ;

Butler, M. O. ;

Middleton, M. R. ;

Maio, M. ;

Atkinson, V. ;

Queirolo, P. ;

Gonzalez, R. ;

Kudchadkar, R. R. ;

Smylie, M. ;

Meyer, N. ;

Mortier, L. ;

Atkins, M. B. ;

Long, G. V. ;

Bhatia, S. ;

Lebbe, C. ;

Rutkowski, P. ;

Yokota, K. ;

Yamazaki, N. ;

Kim, T. M. ;

de Pril, V. ;

Sabater, J. ;

Qureshi, A. ;

Larkin, J. ;

Ascierto, P. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) :1824-1835

← 1 2 →